Microscale culture of human liver cells for drug development
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Tissue function depends on hierarchical structures extending from single cells ( approximately 10 microm) to functional subunits (100 microm-1 mm) that coordinate organ functions. Conventional cell culture disperses tissues into single cells while neglecting higher-order processes. The application of semiconductor-driven microtechnology in the biomedical arena now allows fabrication of microscale tissue subunits that may be functionally improved and have the advantages of miniaturization. Here we present a miniaturized, multiwell culture system for human liver cells with optimized microscale architecture that maintains phenotypic functions for several weeks. The need for such models is underscored by the high rate of pre-launch and post-market attrition of pharmaceuticals due to liver toxicity. We demonstrate utility through assessment of gene expression profiles, phase I/II metabolism, canalicular transport, secretion of liver-specific products and susceptibility to hepatotoxins. The combination of microtechnology and tissue engineering may enable development of integrated tissue models in the so-called 'human on a chip'.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, hepatic models that utilize conventional 2D mono-and co-cultures of normal and diseased human cells fail to mimic the complex threedimensional (3D) in vivo microenvironment and extracellular matrix (ECM) support [16,19,20].”
From A liver-on-a-chip platform with bioprinted hepatic spheroids (2016) · cites this paper as [16]
In the citing paper
“The oxygenated or microfabricated co-cultures have been reported to allow HHs to retain metabolic function for a few weeks; however, these cells lose their proliferative capacity (Khetani and Bhatia, 2008; Kidambi et al., 2009”
From In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity (2018) · cites this paper as Khetani and Bhatia, 2008
Citations
Cites
Geometric Control of Cell Life and Death
Chen, C. S., Mrksich, M., Huang, S., Whitesides, G. M., & Ingber, D. E. (1997) · Science · doi:10.1126/science.276.5317.1425 · Cited by 4,657 · cited 1×
“Over the last decade, microtechnology tools have emerged to probe biomedical phenomena at relevant length scales and to miniaturize and parallelize biomedical assay”
BackgroundRheinwatd, J. G., & Green, H. (1975) · Cell · doi:10.1016/s0092-8674(75)80001-8 · Cited by 4,537
Soft Lithography in Biology and Biochemistry
Whitesides, G. M., Ostuni, E., Takayama, S., Jiang, X., & Ingber, D. E. (2001) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.3.1.335 · Cited by 2,607 · cited 1×
“Our approach incorporates 'soft lithography' techniques, using reusable, elastomeric molds of microfabricated structures to overcome limitations of photolithograph”
MethodIdiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054 · cited 1×
“The need for such models is underscored by the high rate of pre-launch and post-market attrition of pharmaceuticals due to liver toxicit”
BackgroundGenome-wide expression monitoring in Saccharomyces cerevisiae
Wodicka, L., Dong, H., Mittmann, M., Ho, M.-H., & Lockhart, D. J. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1359 · Cited by 973
Bhatia, S. N., Balis, U. J., Yarmush, M. L., & Toner, M. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.14.1883 · Cited by 890
Self-citationWilkening, S., Stahl, F., & Bader, A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1035 · Cited by 794 · cited 1×
“Although hepatocarcinoma-derived cell lines and immortalized hepatocytes can be reproducible and inexpensive, they display abnormal levels of liver-specific function”
BackgroundHewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., et al. (2007) · Drug Metabolism Reviews · doi:10.1080/03602530601093489 · Cited by 735
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
LeCluyse, E. L. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00135-x · Cited by 477
Liver cell models in in vitro toxicology.
Guillouzo, A. (1998) · Environmental Health Perspectives · doi:10.1289/ehp.98106511 · Cited by 385
Faucette, S. R., Hawke, R. L., Lecluyse, E. L., Shord, S. S., Yan, B., Laethem, R. M., & Lindley, C. M. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0026-895x(24)12054-8 · Cited by 353
Microfabrication in Biology and Medicine
Voldman, J., Gray, M. L., & Schmidt, M. A. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.401 · Cited by 344
Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., Burton, L. A., Krueger, L. A., Downey, A. D., Czerwinski, M., Forster, J., Ribadeneira, M. D., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.4.421 · Cited by 338 · cited 1×
“CYP450 activity in micropatterned cocultures was assessed over several weeks using fluorometric substrates for high-throughput screening and isoenzyme-specific probes requiring chromatographic separation of metabolite”
MethodAdvances in bioartificial liver devices
Allen, J. W., Hassanein, T., & Bhatia, S. N. (2001) · Hepatology · doi:10.1053/jhep.2001.26753 · Cited by 326
Self-citationSivaraman, A., Leach, J., Townsend, S., Iida, T., Hogan, B., Stolz, D., Fry, R., Samson, L., Tannenbaum, S., & Griffith, L. (2005) · Current Drug Metabolism · doi:10.2174/138920005774832632 · Cited by 310
Liver-Specific Functional Studies in a Microfluidic Array of Primary Mammalian Hepatocytes
Kane, B. J., Zinner, M. J., Yarmush, M. L., & Toner, M. (2006) · Analytical Chemistry · doi:10.1021/ac051856v · Cited by 264
Gebhardt, R., Hengstler, J. G., Müller, D., Glöckner, R., Buenning, P., Laube, B., Schmelzer, E., Ullrich, M., Utesch, D., Hewitt, N., et al. (2003) · Drug Metabolism Reviews · doi:10.1081/dmr-120023684 · Cited by 258
Making Better Drugs: Decision Gates in Non-Clinical Drug Development
Pritchard, J. F., Jurima-Romet, M., Reimer, M. L. J., Mortimer, E., Rolfe, B., & Cayen, M. N. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1131 · Cited by 246
Donato, M. T., Jiménez, N., Castell, J. V., & Gómez-Lechón, M. J. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.7.699 · Cited by 214 · cited 1×
“Microsomes are used in high-throughput systems to identify enzymes involved in drug metabolis”
MethodInhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole
Huang, H., Wang, H., Sinz, M., Zoeckler, M., Staudinger, J., Redinbo, M. R., Teotico, D. G., Locker, J., Kalpana, G. V., & Mani, S. (2007) · Oncogene · doi:10.1038/sj.onc.1209788 · Cited by 213
Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes
LeCluyse, E. L., Madan, A., Hamilton, G., Carroll, K., DeHaan, R., & Parkinson, A. (2000) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(2000)14:4<177::aid-jbt1>3.0.co;2-4 · Cited by 196
Viravaidya, K., & Shuler, M. L. (2004) · Biotechnology Progress · doi:10.1021/bp034238d · Cited by 184 · cited 1×
“The combination of microtechnology and tissue engineering may enable development of integrated tissue models in the so-called 'human on a chip”
BackgroundStresser, D. M., Turner, S. D., Blanchard, A. P., Miller, V. P., & Crespi, C. L. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.845 · Cited by 161
Cytochrome P-450 mRNA Expression in Human Liver and Its Relationship with Enzyme Activity
Rodríguez‐Antona, C., Donato, M. T., Pareja, E., Gómez‐Lechón, M. J., & Castell, J. V. (2001) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.2001.2499 · Cited by 145 · cited 1×
“Additionally, we confirmed reports that mRNA levels do not always correlate quantitatively with enzymatic activit”
BackgroundEngineering tissues for in vitro applications
Khetani, S. R., & Bhatia, S. N. (2006) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2006.08.009 · Cited by 141
Self-citationRichert, L., Liguori, M. J., Abadie, C., Heyd, B., Mantion, G., Halkic, N., & Waring, J. F. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007708 · Cited by 136
Khetani, S. R., Szulgit, G., Del Rio, J. A., Barlow, C., & Bhatia, S. N. (2004) · Hepatology · doi:10.1002/hep.20351 · Cited by 123 · cited 1×
“These findings are consistent with our rodent data in that 3T3 fibroblasts stabilized hepatocyte functions across both specie”
ResultSelf-citationHepatotoxicity of thiazolidinediones
Isley, W. L. (2003) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2.6.581 · Cited by 99 · cited 1×
“When we compared compounds within the thiazolidinedione drug class, troglitazone (Rezulin; a hypoglycemic withdrawn by the FDA due to hepatotoxicity) was much more acutely toxic than its structural analogs, rosiglitazone (Avandia) and pioglitazone (Actos, Glustin), known to have a larger margin of safety and approved…”
BackgroundCorlu, A., Ilyin, G. P., Cariou, S., Lamy, I., Loyer, P., & Guguen‐Guillouzo, C. (1997) · Cell Biology and Toxicology · doi:10.1023/a:1007475122321 · Cited by 63 · cited 1×
“Our approach allows us to surround hepatocyte colonies with various liver- or nonliver-derived strom”
MethodZeilinger, K., Sauer, I. M., Pleß, G., Strobel, C., Rudzitis, J., Wang, A., Nüssler, A. K., Grebe, A., Mao, L., Auth, S. H. G., et al. (2002) · Alternatives to Laboratory Animals · doi:10.1177/026119290203000506 · Cited by 56
Eschbach, E., Chatterjee, S. S., Nöldner, M., Gottwald, E., Dertinger, H., Weibezahn, K., & Knedlitschek, G. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20360 · Cited by 54
Turncliff, R. Z., Tian, X., & Brouwer, K. L. R. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.02.004 · Cited by 53
Metabolic interactions of methoxsalen and coumarin in humans and mice
Mäenpää, J., Juvonen, R. O., Raunio, H., Rautio, A., & Pelkonen, O. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90558-4 · Cited by 52
Depletion of hepatic UDP-glucuronic acid by drugs that are glucuronidated.
Howell, S. R., Hazelton, G. A., & Klaassen, C. D. (1986) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38967-6 · Cited by 49
Kaihara, S., Kim, S. H., Kim, B., Mooney, D. J., Tanaka, K., & Vacanti, J. P. (2000) · Journal of Pediatric Surgery · doi:10.1053/jpsu.2000.9298 · Cited by 46
The effect of probenecid on paracetamol metabolism and pharmacokinetics
Kamali, F. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315313 · Cited by 43 · cited 1×
“or probenecid (Benemid, Probalan) to inhibit glucuronidatio”
Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M. A., Gagne, G., Fagerland, J. A., & Ulrich, R. G. (2003) · Toxicology in Vitro · doi:10.1016/s0887-2333(03)00102-4 · Cited by 34
Apparent Potentiation by Phenobarbital of Hepatotoxicity from Small Doses of Acetaminophen
Jh, P. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-3-403_1 · Cited by 34
A stereotypic, transplantable liver tissue-culture system
Naughton, B. A., Sibanda, B., Weintraub, J. P., Román, J. S., & Kamali, V. (1995) · Applied Biochemistry and Biotechnology · doi:10.1007/bf02787912 · Cited by 19
Granhall, C., Floby, E., Nordmark, A., Orzechowski, A., Thörne, A., Tybring, G., & Sohlenius-Sternbeck, A.-K. (2002) · Xenobiotica · doi:10.1080/0049825021000012646 · Cited by 10
Cited by
Reconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Self-citationUygun, B. E., Soto-Gutierrez, A., Yagi, H., Izamis, M.-L., Guzzardi, M. A., Shulman, C., Milwid, J., Kobayashi, N., Tilles, A., Berthiaume, F., et al. (2010) · Nature Medicine · doi:10.1038/nm.2170 · Cited by 1,370
“Primary hepatocytes are known to require between 7 and 10 d in culture before their metabolic activity and gene transcription levels stabiliz”
BackgroundHighly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Metadata
- Authors
- Khetani, S. R., & Bhatia, S. N.
- Affiliations
- Massachusetts Institute of Technology (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Bhatia, Sangeeta N
- Venue
- Nature Biotechnology
- Published
- 2007-11-18
- Volume
- 26
- Issue
- 1
- Pages
- 120-126
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2023296392
- Cited by
- 1,219
- References
- 41
- Citations by year
- 2026: 19 · 2025: 41 · 2024: 36 · 2023: 49 · 2022: 64 · 2021: 56 · 2020: 68 · 2019: 73 · 2018: 81 · 2017: 86 · 2016: 93 · 2015: 77 · 2014: 76 · 2013: 90 · 2012: 75
- FWCI
- 38.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- human liver cells, liver-on-a-chip, hepatotoxicity, drug development, phase I and II metabolism, canalicular transport, hepatocyte secretion, gene expression profiling, tissue engineering, microtechnology
- MeSH terms
- Biological Assay, Cells, Cultured, Equipment Design, Humans, Miniaturization, Drug Design, Flow Injection Analysis, Cell Culture Techniques, Equipment Failure Analysis, Hepatocytes, Microfluidic Analytical Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.